PROCEPT BioRobotics Corp. to Report First Quarter 2022 Financial Results on May 5, 2022 and attend the 2022 Bank of America Healthcare Conference on May 11, 2022
13 4월 2022 - 5:02AM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced it will report
financial results for the first quarter 2022 after market close on
Thursday, May 5, 2022. The company’s management will webcast a
corresponding conference call beginning at 1:30 p.m. Pacific Time /
4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do
so by dialing (866)-374-5140 for domestic callers or (808)-238-9813
for international callers, using conference ID: 25960799. Live
audio of the webcast will be available on the “Investors” section
of the company’s website at:
https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors”
section of the company’s website at:
https://ir.procept-biorobotics.com. The webcasts will be available
for replay for at least 90 days after the event.
Additionally, members of management will be attending the 2022
Bank of America Healthcare Conference in Las Vegas on Wednesday,
May 11, 2022. Management will be hosting a fireside chat
presentation at 2:00 pm Pacific Time / 5:00 pm Eastern Time.
A live webcast of each event, as well as an archived recording,
will be available on the “Investors” section of the company’s
website at: https://ir.procept-biorobotics.com. The webcasts
will be archived and available for replay for at least 90 days
after the event.
About PROCEPT BioRobotics CorporationPROCEPT is
a surgical robotics company focused on advancing patient care by
developing transformative solutions in urology. PROCEPT develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
designed Aquablation therapy to deliver effective, safe and durable
outcomes for males suffering from lower urinary tract symptoms, or
LUTS, due to BPH that are independent of prostate size and shape or
surgeon experience. PROCEPT has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 100 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Investor Contact:Gilmartin GroupMatt Bacso,
CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024